Roya Hakimzadeh

Roya Hakimzadeh has a diverse work experience spanning various roles and companies. Roya is currently serving as the Director of Patient Advocacy at Bloom Science, Inc. since February 2023. Prior to that, they worked at WCG as the Director of Patient Advocacy and Clinical Trials Diversity from April 2022 to February 2023.

Before their role at WCG, Roya held multiple positions at REGENXBIO Inc. Roya served as an Associate Director of Patient Advocacy from February 2021 to April 2022, where they contributed to patient-focused initiatives. Prior to that, they were an Associate Director of Patient Services and Insights from February 2020 to February 2021, where they provided support and insights to patients. Roya also worked as a Senior Manager of Patient Identification Support and Analytics from October 2018 to February 2020, where they supported patient identification processes.

Roya's work experience also includes roles at Vanda Pharmaceuticals, where they worked as a Marketing Associate from January 2017 to July 2018. Roya also served as a Case Manager II from August 2015 to July 2018 and a Case Manager/Health Educator from October 2014 to August 2015, where they played a crucial role in managing cases and educating patients.

Furthermore, Roya's experience includes working as a Medical Assistant at the Allergy, Asthma & Immunology Center from June 2012 to August 2014. Roya gained research experience as a Research Intern at the National Institute of Arthritis and Musculoskeletal and Skin Diseases from September 2009 to May 2010.

Overall, Roya Hakimzadeh has built a strong background in patient advocacy, clinical trials diversity, patient services and insights, and patient identification support throughout their career.

Roya Hakimzadeh completed their Bachelor of Science (B.S.) in Biology/Biological Sciences, General at American University from 2010 to 2013. From 2014 to 2016, they pursued their Master of Professional Studies (M.P.S.) in Biotechnology at the University of Maryland Baltimore County. In July 2017, they obtained the GOETHE-ZERTIFIKAT A2 certification from the Goethe-Institut Washington DC.